Advancing Treatment of
Bladder Cancer
A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.
InforMEDical Communications, Inc. •
83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com
This CME has expired.
For a list of active online CME, please click here.
CME Information
Up to AMA PRA Category Credit(s)™
Release date: July 2008 Valid through: July 2009
Course Material: Online Only
Receiving CME Credit
To receive online CME credit for this activity, read the full activity then click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This educational activity is intended for oncologists, urologists and other medical professionals who assess, treat and counsel patients with bladder cancer.
Educational Objectives
Following completion of this activity, participants should be able to:
- Assess appropriate use of systemic chemotherapy in the management of muscle invasive bladder cancer.
- Assess optimal approaches to treating superficial bladder cancer, including BCG + interferon and addressing patients who fail BCG therapy.
- Integrate this information into their practice of treatment and patient counseling.
Educational Need
Physicians who manage and counsel patients with bladder cancer need to assess and integrate into their practice of treatment and patient counseling: (a) the current framework for assessing appropriate use of systemic chemotherapy for muscle-invasive disease and (b) optimal approaches to treating superficial bladder, particularly for BCG-resistant disease.
Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
Supported by educational grants from Bristol-Myers Squibb Company, Eli Lilly and Company and Schering Corporation.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
The program faculty disclosed the following financial relationships: Colin P. N. Dinney: Paid consultant: Schering Plough, Novartis, Bristol Myers Squibb; Research support: AstraZeneca, GlaxoSmithKline; Speakers Bureau: SciMed, Abbot/Vysis. Maha H. A. Hussain: Paid consultant: Lilly; Research funding: Pfizer. InforMEDical staff who contributed to planning and editing content, and individuals who provided independent peer review, have no financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, contradictions and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.